Antirheumatic drugs for cardiovascular disease prevention: The case for colchicine

Research output: Contribution to journalReview articleAcademicpeer-review


We summarised four pivotal Randomised Controlled Trials (RCTs) with antirheumatic drugs on the secondary prevention of cardiovascular events. The favourable effects of canakinumab and colchicine confirm (low-grade) inflammation as an independent risk factor for cardiovascular events. While colchicine might be the first drug in the clinic, we expect that this is only the first in a future series of anti-inflammatory drugs used in secondary prevention of cardiovascular events.
Original languageEnglish
Article numbere001560
JournalRMD Open
Issue number1
Publication statusPublished - 16 Mar 2021

Cite this